SURVIVAL OF PATIENTS WITH ADVANCED HER2+ BREAST CANCER. ANALYSIS OF A CANCER CENTER DATABASE
Características clínicas y pronóstico de pacientes con cáncer de mama HER2 positivo avanzado, en la era antes y después de terapias anti HER2
Author
Sánchez, César; Profesor asistente Departamento Hematología-OncoloPontifica Universidad Católica de Chile
Domínguez, Francisco; Facultad de Medicina. Pontifica Universidad Católica de Chile
Galindo, Héctor; Facultad de Medicina. Pontifica Universidad Católica de Chile
Camus, Mauricio; Facultad de Medicina. Pontifica Universidad Católica de Chile
Oddo, David; Facultad de Medicina. Pontifica Universidad Católica de Chile
Villarroel, Alejandra; Facultad de Medicina. Pontifica Universidad Católica de Chile
Razmilic, Dravna; Facultad de Medicina. Pontifica Universidad Católica de Chile
Navarro, María Elena; Facultad de Medicina. Pontifica Universidad Católica de Chile
Perez-Sepúlveda, Alejandra; Facultad de Medicina. Pontifica Universidad Católica de Chile
Medina, Lidia; Centro de Cancer. Red de Salud UC Christus.
López, Valeska; Centro de Cancer. Red de Salud UC Christus.
Acevedo, Francisco; Facultad de Medicina. Pontifica Universidad Católica de Chile
Abstract
Background: HER2 breast cancer (BC) subtype overexpresses the Human Epidermal growth factor Receptor type-2 (HER2) and is characterized by its aggressiveness and its high sensitivity to monoclonal antibody-based HER2-targeted therapies. Aim: To assess the prognosis and evaluate the impact of novel anti-HER2 therapies on advanced HER2+ BC patients treated at our institution over the last decades. Material and methods: Analysis of the patient database at a cancer center of a university hospital. Information about the subtype of cancer was obtained in 2149 of 2724 patients in the database. Eighteen percent of the latter were HER2+. We analyzed data of 83 of these patients with advanced disease. Results: Median overall survival (OS) was 24 months. For patients treated between 1997-2006 median OS was 17 months and for those treated in the period 2007-2017 median OS was 32 months (p=0.09). Conclusions: A non-significant trend towards better survival in the last decade was observed. HER2+ BC overall survival has improved in our center. This can be probably attributed to the use of novel more effective anti-HER2 therapies. Background: HER2 breast cancer (BC) subtype overexpresses the Human Epidermal growth factor Receptor type-2 (HER2) and is characterized by its aggressiveness and its high sensitivity to monoclonal antibody-based HER2-targeted therapies. Aim: To assess the prognosis and evaluate the impact of novel anti-HER2 therapies on advanced HER2+ BC patients treated at our institution over the last decades. Material and methods: Analysis of the patient database at a cancer center of a university hospital. Information about the subtype of cancer was obtained in 2149 of 2724 patients in the database. Eighteen percent of the latter were HER2+. We analyzed data of 83 of these patients with advanced disease. Results: Median overall survival (OS) was 24 months. For patients treated between 1997-2006 median OS was 17 months and for those treated in the period 2007-2017 median OS was 32 months (p=0.09). Conclusions: A non-significant trend towards better survival in the last decade was observed. HER2+ BC overall survival has improved in our center. This can be probably attributed to the use of novel more effective anti-HER2 therapies.
Metadata
Show full item recordRelated items
Showing items related by title, author, creator and subject.
-
SURVIVAL OF PATIENTS WITH METASTATIC BREAST CANCER ACCORDING TO PATHOLOGICAL TYPES OF TUMORS.
Sánchez R, César; Instructor asociado Departamento Hematología-Oncologia. Pontifica Universidad Católica de Chile; Acevedo C, Francisco; Pontifica Universidad Católica de Chile; Petric G, Militza; Pontifica Universidad Católica de Chile; Galindo A, Héctor; Domínguez C, Francisco; León R, Augusto; Razmilic V, Dravna; Ceballos, Carolina; Espinoza, Fernando; Navarro O, Maria Elena; Oddó B, David; Camus A, Mauricio. Revista Médica de Chile; Vol. 142, núm. 4 (2014): ABRIL 2014 -
“Hacia la evaluación de Chile Crece Contigo: Resultados psicosociales del estudio piloto”
Bedregal, Paula; Psicóloga del Departamento de Salud Publica. Escuela de Medicina. Pontificia Universidad Católica de Chile. Santiago, Chile; Hernández, Viviana; Psicóloga del Departamento de Salud Publica. Escuela de Medicina. Pontificia Universidad Católica de Chile. Santiago,; Prado, Paulina; Socióloga del Instituto de Sociología. Facultad de Ciencias Sociales. Pontificia Universidad Católica de Chile. Santiago; Castañón, Carla; Doctor en estadística. Departamento de Salud Pública. Escuela de Medicina. Pontifica Universidad Católica de Chile; Mingo, Verónica; Doctor en estadística. Departamento de Salud Pública. Escuela de Medicina. Pontifica Universidad Católica de Chile; de la Cruz, Rolando; Doctor en estadística. Departamento de Salud Pública. Escuela de Medicina. Pontifica Universidad Católica de Chile. Revista Médica de Chile; Vol. 138, núm. 6 (2010): JUNIO -
Vejez y cáncer de mama, el desafío del Siglo 21.
Sánchez R, César; Instructor asociadoDepartamento Hematología-OncologíaFacultad de medicinaPontifica Universidad Católica de Chile. Revista Médica de Chile; Vol. 140, núm. 5 (2012): MAYO 2012